Barely Significant
← all excerpts

The efficacy and safety of antibodies targeting PD-1 for treatment in advanced esophageal cancer: A systematic review and meta-analysis.

Transl Oncol · 2021 · PMC8042180 · PMID 33784583

Europe PMCDOI
2
hedged sentences
0.0600
closest p · 1.2× alpha
0.0600
boldest claim

The sentences

a near significant trendP = 0.06so close (0.05 < p ≤ 0.1)
In addition, the difference of ORR benefit obtained a near significant trend (OR = 1.92; 95% CI: 0.98–3.72; P = 0.06; and heterogeneity: P = 0.006) ( Fig. 2 C). 3.3 Efficacy outcomes of PD-1 inhibitor versus chemotherapy in ESCC Meanwhile, we analyzed the patients with ESCC to figure out the benefit of anti-PD-1 therapy.

also in 33 other papers

a near-significant trendP = 0.06so close (0.05 < p ≤ 0.1)
Nevertheless, the ORR benefit difference obtained a near-significant trend ( P = 0.06), which needs to be compared in more randomized studies.

also in 290 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.